{
    "ticker": "AVPT",
    "name": "Avectas Limited",
    "description": "Avectas Limited is a biotechnology company focused on advancing cell therapy products for cancer and other life-threatening diseases. Founded in 2013 and based in Dublin, Ireland, Avectas is at the forefront of developing next-generation cell therapy solutions that enable the efficient and effective manufacturing of engineered cell therapies. Their proprietary Solupore technology is designed to enhance the transfection of cells, allowing for more effective genetic modifications. This technology aims to simplify the process of delivering therapeutic genes to cells, ultimately improving the performance and safety of cell therapies. Avectas collaborates with biotechnology and pharmaceutical partners to expedite the development of innovative cell therapies, addressing some of the most pressing challenges in the field. With a strong emphasis on research and development, Avectas is committed to transforming the treatment landscape for patients suffering from cancer and other severe conditions through novel and effective cell-based therapies. The company\u2019s mission is to bring hope to patients by delivering advanced therapeutic options that can significantly impact their quality of life.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Dublin, Ireland",
    "founded": "2013",
    "website": "https://www.avectas.com",
    "ceo": "John O'Connor",
    "social_media": {
        "twitter": "https://twitter.com/Avectas",
        "linkedin": "https://www.linkedin.com/company/avectas/"
    },
    "investor_relations": "https://www.avectas.com/investors",
    "key_executives": [
        {
            "name": "John O'Connor",
            "position": "CEO"
        },
        {
            "name": "Peter O'Leary",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapy",
            "products": [
                "Solupore Technology"
            ]
        }
    ],
    "seo": {
        "meta_title": "Avectas Limited | Innovating Cell Therapy Solutions",
        "meta_description": "Avectas Limited is a leader in biotechnology, specializing in advanced cell therapy products for cancer treatment. Discover our innovative technologies and commitment to patient care.",
        "keywords": [
            "Avectas",
            "Cell Therapy",
            "Biotechnology",
            "Cancer Treatment",
            "Gene Therapy"
        ]
    },
    "faq": [
        {
            "question": "What does Avectas specialize in?",
            "answer": "Avectas specializes in developing innovative cell therapy solutions for cancer and other life-threatening diseases."
        },
        {
            "question": "Where is Avectas headquartered?",
            "answer": "Avectas is headquartered in Dublin, Ireland."
        },
        {
            "question": "When was Avectas founded?",
            "answer": "Avectas was founded in 2013."
        },
        {
            "question": "What technology does Avectas use?",
            "answer": "Avectas uses its proprietary Solupore technology to enhance the transfection of cells for cell therapy."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NTLA",
        "ZGNX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ]
}